icd 10 code for her2 positive breast cancer

Release time ：Dec-26,2024

Breast cancer that tests positive for the HER2 protein is categorized under ICD-10 code C50.931. This form of breast cancer is relatively complex due to the excessive presence of HER2 protein on the surface of tumor cells, which fuels the proliferation and metastasis of cancer cells. Treatment approaches for HER2-positive breast cancer often involve targeted therapies designed to inhibit the function of the HER2 protein.

Throughout the treatment, patients may receive a combination of therapies including chemotherapy, radiotherapy, and endocrine therapy. For HER2-positive breast cancer, trastuzumab (Herceptin) is a frequently prescribed targeted therapy that binds to the HER2 protein, interrupting its signaling pathways to suppress the growth of cancer cells. Additionally, pertuzumab (Perjeta) is another targeted therapy that targets HER2-positive breast cancer by binding to distinct regions of the HER2 protein, thereby enhancing treatment efficacy.

Beyond pharmacological interventions, patients are also required to have regular imaging assessments such as ultrasound, CT, and MRI to evaluate tumor characteristics like size, location, and morphology, facilitating timely adjustments to the treatment plan. Concurrently, patients should focus on maintaining a healthy lifestyle by managing diet, exercise, and psychological well-being, which can bolster immune function and aid in coping with the various challenges encountered during treatment.

In conclusion, HER2-positive breast cancer is a complex condition that necessitates a multifaceted therapeutic approach. Patients must be vigilant about their health status, actively engage with their healthcare providers' treatment plans, and strive to enhance treatment outcomes.